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Neuroprotective strategies are an unmet medical need for Parkinson's disease. Fibroblast growth factor
20 (FGF20) enhances survival of cultured dopaminergic neurons but little is known about its in vivo
potential. We set out to examine whether manipulation of the FGF20 system affected nigrostriatal tract
integrity in rats, to identify which fibroblast growth factor receptors (FGFRs) might reside on dopami-
nergic neurons and to discover the source of endogenous FGF20 in the substantia nigra (SN). Male
Sprague Dawley rats were subject to a partial 6-OHDA lesion alongside treatment with exogenous FGF20
or an FGFR antagonist. Behavioural readouts and tyrosine-hydroxylase (TH) immunohistochemistry were
used to evaluate nigrostriatal tract integrity. Fluorescent immunohistochemistry was used to examine
FGFR subtype expression on TH-positive dopamine neurons and FGF20 cellular localisation within the
SN. FGF20 (2.5 mg/day) significantly protected TH-positive cells in the SN and terminals in the striatum,
while reducing the development of motor asymmetry at 5, 8 and 11 days post lesion. Conversely, the
FGFR antagonist PD173074 (2mg/kg) significantly worsened both the 6-OHDA lesion and resultant motor
asymmetry. Within the SN, TH-positive cells expressed FGFR1, 3 and 4 while FGF20 co-localised with
GFAP-positive astrocytes. In conclusion, FGF20 protects dopaminergic neurons in vivo, an action likely
mediated through activation of FGFRs1, 3 or 4 found on these neurons. Given FGF20 is localised to as-
trocytes in the adult SN, endogenous FGF20 provides its protection of dopamine neurons through a
paracrine action. Boosting the endogenous FGF20 production might offer potential as a future thera-
peutic strategy in Parkinson's disease.
© 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Parkinson's disease (PD) is a neurodegenerative condition
characterised by both motor and non-motor symptoms. The motor
signs largely reflect the progressive loss of dopaminergic neurons in
the substantia nigra pars compacta (SNc) and the ensuing striatal
dopamine depletion. While current treatments like levodopa or
dopamine agonists provide some relief of motor symptoms, there
remains no established treatment that protects the dopaminergic
neurons, leaving degeneration to progress unchecked. This lack of
effective disease-modifying therapy may reflect the multifactorial
nature of the underlying pathogenesis of PD which ranges fromtitute of Psychiatry, Psychol-
Diseases, WW1.28, Hodgkin
r Ltd. This is an open access articleoxidative stress and excitotoxicity, through mitochondrial
dysfunction and neuro-inflammation to genetic predisposition and
protein mishandling (AlDakheel et al., 2014). Tackling these path-
ogenic mechanisms individually might not be sufficient to prevent
neurodegeneration. An alternative approach is to increase survival
of vulnerable neurons through boosting neurotrophic factors. Given
the recent systematic and meta-analysis which concluded that
glial-derived neurotrophic factor (GDNF) and neurturin do not
improve motor symptoms in people with Parkinson's (Hegarty
et al., 2017) it is timely to consider alternative factors that may
hold potential.
Fibroblast growth factors (FGFs) have already shown promise in
rodent models of PD; for example, FGF2 (Timmer et al., 2007) and
FGF20 (Sleeman et al., 2012). Of these, FGF20 has a more restricted
distribution (Ernfors et al., 1990; Jeffers et al., 2001) so it presents a
more attractive target. FGF20 is selectively expressed in the adult
brain, with little to no expression in healthy peripheral tissues
(Jeffers et al., 2001; Kirikoshi et al., 2000; Ohmachi et al., 2000).under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Eugene.L. Boshoff et al. / Neuropharmacology 137 (2018) 156e163 157Within the brain, mRNA encoding FGF20 shows further regional
selectivity, with highest levels of expression in the cerebellum and
substantia nigra (SN) (Jeffers et al., 2001). In vitro, FGF20 protects
cultured ventral mesencephalic (VM) dopaminergic neurons
against various toxic insults including serum withdrawal, gluta-
mate and 6-hydroxydopamine (6-OHDA) (Murase and McKay,
2006; Ohmachi et al., 2000; Sleeman et al., 2012). Moreover,
in vivo, FGF20 infusion protects against loss of dopaminergic neu-
rons in the SNc and against ensuing motor impairments in a rat
model of PD bearing a full 6-OHDA-induced lesion of the nigros-
triatal tract (Sleeman et al., 2012).
The protective effects of FGF20 in vitro are reduced in the
presence of a broad spectrum FGF receptor (FGFR) antagonist or
selective MEK1/2 inhibitor (Murase and McKay, 2006; Ohmachi
et al., 2003), supporting activation of FGFRs and downstream
phosphorylation cascades of the Akt and MAPK pathways playing a
key role (Ong et al., 2000; Schlessinger, 2000). mRNA species
encoding all FGFRs are found in the brain, with FGFR1, 2 and 3
already reported in SN and striatum (Belluardo et al., 1997; Claus
et al., 2004a, 2004b). FGF20 shows affinity for all FGFRs: c iso-
forms of FGFR1, 2 and 3, and FGFR4 (Ohmachi et al., 2003; Zhang
et al., 2006). While the protective effects of FGF20 on dopami-
nergic neurons are likely to be at least partly mediated through
FGFR1, since FGFR1 immunoreactivity is confirmed on dopami-
nergic TH-positive neurons in rat (Sleeman et al., 2012) and human
(Walker et al.,1998) SNc, the involvement of other FGFRs remains to
be established.
A role for endogenous FGF20 in supporting the survival of
dopaminergic neurons is suggested by the findings that prevention
of endogenous FGF20 binding to FGFR1c (using the chimeric pro-
tein FGFR1cdFc) led to reduced DA neuron survival in VM mixed
cultures (Murase and McKay, 2006). However, whether endoge-
nous FGF20 impacts upon the survival of adult dopaminergic
neurons in vivo remains to be determined, as does the nature of any
cell types that produce FGF20 in vivo.
The aim of these studies was therefore to further explore the
protective role of FGF20 in the nigrostriatal tract in vivo. We
hypothesised that exogenous FGF20 would protect against a partial
6-OHDA lesion of the nigrostriatal tract in rats, while treatment
with an FGFR antagonist would exacerbate the size of this partial 6-
OHDA lesion supporting a protective role for endogenous FGF20.
Additionally, we set out to discover which FGFRs were present on
dopaminergic neurons in the SNc. Finally, we examined the cellular
localisation of FGF20 protein to identify whether dopaminergic
neurons or astrocytes were the source of endogenous FGF20 pro-
duction in the SN.
2. Material and methods
2.1. Subjects
All studies were carried out in accordance with the UK Animals
Scientific Procedures Act (ASPA) and were approved by King's
College London animal ethics review panel. A total of 44 adult male
Sprague Dawley rats (7-9 weeks; 250-280g; Charles River, Kent UK)
were maintained on a 12:12 h light:dark cycle with food and water
available ad libitum. Of the 44 rats, n¼ 22 were used for the FGF20
supra-nigral infusion study, n¼ 19 were used for the FGFR antag-
onist study and n¼ 3 were used for localisation of FGF20 and
FGFR1-4.
2.2. FGF20 supra-nigral infusion in 6-OHDA lesioned rats
Under general anaesthesia (ketamine, 75 mg/kg, i. p.; medeto-
midine, 0.5 mg/kg, i. p), a dual-barrelled cannula was implanted2 mm above the right SNc at coordinates AP, þ3.7 mm;
ML, þ2.0 mm; DV, þ4.2 mm, relative to the inter-aural line,
(Paxinos and Watson, 1993). One barrel was attached via PVC
tubing to a pre-filled Alzet 1007D osmotic mini-pump, implanted
subcutaneously on the rostral hindback of the rat. Pumps were pre-
filled with freshly prepared FGF20 (Peprotech) 83.4 ng/ml or
208 ng/ml in artificial cerebrospinal fluid (aCSF) containing 100 ng/
ml of rat serum albumin carrier protein or vehicle (aCSF containing
100 ng/ml rat serum albumin). Pumps provided supra-nigral de-
livery at 0.5 ml/h supplying treatment groups with vehicle (n¼ 10),
1 mg/day FGF20 (n¼ 6) or 2.5 mg/day FGF20 (n¼ 6) for 1 day prior to
and 6 days post 6-OHDA lesion.
After 24h treatment infusion, all rats were subject to a partial 6-
OHDA lesion. Rats were pre-treated with desipramine (25mg/kg i.
p.) and pargyline (5mg/kg i. p.). 30 min later, under isoflurane
anaesthesia (5% induction and 2-3% maintenance), 4 mg 6-OHDA in
4 ml 0.02% ascorbate was infused (2 ml/min) via a needle inserted
through the second cannula barrel and extending 2mm further,
into the right SNc.
2.3. FGFR antagonist treatment in 6-OHDA lesioned rats
Rats were treated once daily with the FGFR antagonist,
PD173074 (1 or 2mg/kg s. c.; n¼ 6) or PD173074 vehicle (10%
DMSO, 10% PEG200 in PBS, pH 7.6; n¼ 7) for 3 days prior to and 5
days post 6-OHDA lesioning, which was performed exactly as
described above.
2.4. Measuring motor deficits
Cylinder test assessment of forelimb akinesia was performed in
both studies 1 day prior to 6-OHDA lesioning (baseline), and on
days 5, 8 and 11 post-lesion (FGF20 study) or days 3 and 5 post
lesion (FGFR antagonist study) as previously described (Sleeman
et al., 2012). In the FGFR antagonist study, motor asymmetry was
additionally measured, 6 days post lesion, using amphetamine-
induced rotation test as previously described (Betts et al., 2012).
Briefly, animals were injected with amphetamine (5mg/kg i. p.)
and the number of net ipsiversive rotationsmonitored using rotarat
software over a 70-min period.
2.5. Tyrosine hydroxylase (TH) immunohistochemistry
Brains were removed on day 12 (FGF20 study) or day 7 (FGFR
antagonist study) post 6-OHDA lesioning. Animals were euthanised
by overdose with sodium pentobarbitone (Euthatal; 200mg/ml;
1ml injection) then intracardially perfused with phosphate-
buffered saline followed by 4% paraformaldehyde. Brains were
then removed, fixed in 4% paraformaldehyde then embedded in
paraffin wax. Serial 8 mm sections of rostral, mid and caudal stria-
tum and SN were obtained and processed for TH staining as pre-
viously described (Sleeman et al., 2012).
Digital images of TH-immunostained striatal sections (n ¼ 3
sections per rat each at rostral [AP, þ1.6 mm], medial
[AP, þ0.2 mm] and caudal [AP, -1.4 mm] levels) were acquired
and densitometric analysis, corrected for background cortical
stain, performed using ImageJ software. TH intensity in lesioned
hemisphere was determined as a percentage of intact hemi-
sphere for each animal. Mean percentage TH-immunoreactivity
values did not differ between rostro-caudal levels within a
treatment group. Data were therefore combined across all three
levels, generating a single average value for each animal. Mean
data were calculated per treatment group.
Digital images of the nigral sections were acquired at 10
magnification using a Zeiss brightfield microscope. Viable TH-
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ImageJ software. Average number of nigral TH- positive cells per
section in the lesioned and intact hemisphere of each animal was
taken by averaging the counts from 3 sections at each of the rostral
(AP, -4.8mm), medial (AP, -5.2mm) and caudal (AP, -5.8mm) level
of the SNc. Data were finally expressed as the number of TH-
positive cells remaining in the lesioned SNc as a percentage of
the intact side.
2.6. Localisation of FGF20 and FGFR1-4 in the rat SN
All immunohistochemistry was performed at room temperature
on 8 mm paraffin-embedded sections of the SN from 3 naïve male
Sprague Dawley rats (250g; 7-weeks old; Harlan UK). FGF20 and
tyrosine hydroxylase (TH)/Glial fibrillary acidic protein (GFAP) co-
localisation: Sections were incubated overnight with rat anti-
FGF20 antibody (MAB2547, 1:100) alongside either rabbit anti-TH
antibody (AB152, 1:1000) or rabbit anti-GFAP (Z0334, 1:500), fol-
lowed by incubation for 2h with goat anti-rat AlexaFluor 546
(1:200) and goat anti-rabbit AlexaFluor 488 (1:200) solution con-
taining 1 mg/ml Hoechst 33258. FGFRs and TH co-localisation:
Sections were incubated overnight with rabbit anti-FGFR1 (F5421,
1:100), rabbit anti-FGFR2 (ab10648, 1:100), mouse anti-FGFR3 (sc-
13121, 1:50) or mouse anti-FGFR4 (sc-136988, 1:50) alongside
either mouse anti-TH (MAB318, 1:500) or rabbit anti-TH (AB152,
1:500) before incubation for 2h with goat anti-rabbit AlexaFluor
546 (1:200) or goat anti-mouse AlexaFluor 488 (1:200) solution
containing 1 mg/ml Hoechst 33258. Fluorescence images were ac-
quired using a Zeiss Apotome fluorescent microscope and Axiovi-
sion image analysis software.
2.7. Statistical analysis
Statistical analyses were performed using GraphPad Prism 7.
Cylinder test asymmetry score was compared between treatments
using 2-way Analysis of Variance (ANOVA); differences over time
within a treatment group were assessed using 1-way ANOVA with
Dunnett's post-hoc test. Total net ipsiversive amphetamine-
induced rotations were compared between treatments using a 1-
way ANOVA with Dunnett's post-hoc test. Differences in striatal
TH-immunoreactivity or TH-positive cell counts in the SNc were
compared between treatments using 1-way Analysis of Variance
and Tukey's post-hoc test.
3. Results
3.1. Protective effects of chronic supra-nigral infusion of FGF20 in 6-
hydroxydopamine lesioned rats
Supra-nigral infusion with the higher dose of FGF20 (2.5 mg/day
for 7 days) provided significant protection against the loss of TH-
positive cells in the SNc and striatal TH density quantified at 12
days post lesion in the 6-OHDA partial lesion model (P< 0.05; 1-
way ANOVA with Tukey's post-hoc test). In the lesion hemisphere
of vehicle-treated rats, ~30% of TH-positive cells remained in the
SNc: cell number per section was 105± 2 in the intact side, versus
29± 5 in the lesion side (mean± sem; n¼ 10). In contrast, in the
2.5 mg/day FGF20 infused group ~50% of TH-positive cells remained
in the lesion SNc: cell number per section was 109± 3 in the intact
side versus 54± 6 in lesion (n¼ 6) (Fig. 1a and b). Similarly, in the
lesioned hemisphere of vehicle-treated animals only ~50% of
striatal TH-positive terminals remained, whereas ~80% remained in
the 2.5 mg/day FGF20 group (Fig. 1c and d). FGF20 (1 mg/day for 7d)failed to preserve either TH-positive cells in the SNc or striatal
terminals.
Overall analysis of the data revealed a significant effect of time
on cylinder test performance (P< 0.05; 2-way ANOVA plus Tukey's
post-hoc test). Within-treatment group analyses showed that in
vehicle-infused animals, the contralateral forelimb touches were
significantly reduced at each time post-lesion compared to pre-
lesion (P< 0.001; 1-way ANOVA with Dunnett's post-hoc test). In
contrast, there was no significant reduction compared to pre-lesion
score for animals treated with either dose of FGF20 (Fig. 1e).
3.2. FGFR antagonist infusion exacerbates a partial 6-OHDA lesion
of the nigrostriatal tract
While treatment with FGFR antagonist, PD173074 (1mg/kg/day
for 3 days prior to and 5 days post 6-OHDA) had no impact on the
extent of 6-OHDA partial lesion, the higher dose of PD173074
(2mg/kg/day) enhanced the size of the lesion produced. In vehicle-
treated rats, ~24% of cells remained in the 6-OHDA-lesioned SNc,
whereas significantly fewer (8%) remained in the equivalent region
of PD173074 (2mg/kg)-treated rats (P< 0.05; 1-way ANOVA with
Tukey's post hoc test). Although not significant, striatal TH loss was
also exacerbated following PD173074 treatment (Fig. 2a and b). In
the cylinder test, while use of the contralateral paw significantly
declined over time as expected post 6-OHDA lesion, there was no
worsening apparent with FGFR antagonist treatment (data not
shown). However, in the more sensitive amphetamine-induced
rotation test, animals treated with the higher dose of PD173074
produced significantly higher total rotations post amphetamine
when compared to vehicle-treated animals (P< 0.05; 1-way
ANOVA with Dunnett's post hoc test; Fig. 2c).
3.3. Localisation of FGF20 and FGFR1-4 in the rat SN
The localisation patterns shown are representative of those seen
in sections from n¼ 3 different animals. Immunofluorescent
studies in naïve rat brain revealed an absence of FGF20 staining in
the SNc and no co-localisationwith TH-positive neurons (Fig. 3a). In
contrast, FGF20 staining of a diffuse, punctuate nature was
observed in the neighbouring SNr where FGF20 was seen to co-
localise with the astrocyte marker, GFAP (Fig. 3b). As shown in
Fig. 4, FGFR1, 3 and 4 were each expressed on TH-positive dopa-
minergic cells in the SNc. In contrast, FGFR2 was not expressed on
TH-positive cells.
4. Discussion
While mounting evidence points to a potential protective role
for FGF20 in PD, our understanding of how this might be mediated
is far from complete. This study set out to examine the protective
role played by FGF20 in the nigrostriatal tract in rats. We report that
supra-nigral infusion of FGF20 protects against a partial 6-OHDA
lesion of the nigrostriatal tract, an action most likely mediated
through activation of FGFR1, 3 or 4 receptors that were shown to
co-localise with TH-positive neurons in the SNc. We also found that
FGFR blockade exacerbates the extent of a partial 6-OHDA nigros-
triatal tract lesion, supportive of a protective role for endogenous
FGFs. In the case of FGF20, its absence from TH-positive neurons in
the SNc, yet presence in neighbouring GFAP-positive cells suggests
a paracrine action whereby FGF20 released from astrocytes acti-
vates FGFR1, 3 or 4 on dopaminergic neurons to enhance their
survival. These findings reveal potential therapeutic avenues for
disease modification in Parkinson's disease.
Fig. 1. FGF20 protects against dopamine neuron loss and motor deficits in the partial lesion 6-OHDA rat model. Quantification of (A) TH-positive cells in the lesioned SNc and (B) TH
immunoreactivity in the lesioned striatum, both expressed as a percentage of the intact hemisphere. (C) Representative images of TH staining in the SNc and striatum. Arrow heads
indicate the position of the SNc in the lesioned hemispheres. (D) Quantification of the behavioural asymmetry as measured using cylinder reaching. Data are mean ± SEM, n ¼ 10
(vehicle) or 6 (FGF20 treatment groups); *P < 0.05 compared to vehicle-treated group (A and B); ***P < 0.001 versus pre-lesion score (day -1).
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Fig. 2. FGFR antagonist, PD173074, exacerbates a partial 6-OHDA lesion in rats. Quantification of (A) TH-positive cells in the lesioned SNc and (B) TH immunoreactivity in the
lesioned striatum, both expressed as a percentage of the intact hemisphere. (C) Quantification of the total number of amphetamine-induced rotations. Data are mean ± SEM, n ¼ 7
(vehicle) or 6 (PD173074 treatment groups); *P < 0.05 compared to vehicle-treated group (A and C).
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previously reported for a more profound 6-OHDA lesion model of
late stage PD (Sleeman et al., 2012) and supports a beneficial role
for FGF20 regardless of the severity of the lesion. Given that the
in vitro stability of FGF20 at 37 C (data not shown) was maintained
for 4 days before rapidly declining, we conclude that these bene-
ficial in vivo effects occur during the first few days of 6-OHDA lesion
when degeneration is occurring, pointing to a protective rather
than restorative effect of FGF20. Indeed, using the protocol adopted
here, whereby treatment had started by the time the lesion was
induced, the focus was on determining a protective effect. Addi-
tional studies are required to discover whether FGF20 may also
offer benefits when a lesion is already established, for example as a
result of sprouting of dopaminergic neurons. Such studies will
require extended dosing with FGF20 for between 9 and 12weeks in
order to monitor treatment-induced re-innervation without con-
founding effects of spontaneous re-innervation (Sauer and Oertel,
1994; Kim et al., 2011; Zeng et al., 2012), so alternative delivery
mechanisms are required to achieve this.
That FGFR antagonism exacerbates the size of nigrostriatal tract
lesion produced by 6-OHDA, supports a role for endogenous FGFs in
the survival of dopaminergic neurons. This observation is in line
with the aforementioned findings where block of FGFR1 function
in vitro, led to a reduced survival of VM dopaminergic cultures
(Murase and McKay, 2006). Although neither of these studies can
rule out involvement of other FGFs, these data support the notion
that endogenous FGF20 has a protective role within the SNc. The
source of such FGF20 in the SN is clearly of interest. In their seminal
studies, Ohmachi et al. proposed FGF20 mRNA was preferentially
expressed in dopaminergic neurons in the SNc (Ohmachi et al.,
2000), supporting an autocrine action of this growth factor. How-
ever the persistence of FGF20 mRNA in SN homogenates obtained
from animals post 6-OHDA lesion of the nigrostriatal tract argued in
favour of an alternative source (Grothe et al., 2004). Our findings
support the later notion. We found no evidence for FGF20 immu-
noreactivity in TH-positive dopaminergic neurons in the SNc.
Rather, FGF20 was co-localised with GFAP in the neighbouring SNr.
We therefore propose that FGF20 released from astrocytes within
the SNr diffuses to neighbouring dopaminergic cells in the SNc to
provide protection in a paracrine manner.
The presence of FGF20 in astrocytes in the SNr raises the
intriguing possibility that, during a 6-OHDA induced lesion with
overt inflammatory responses, the infiltration of astrocytes into the
area might lead to a compensatory elevation in endogenous FGF20levels. In animals bearing a partial 6-OHDA lesion, there is no sig-
nificant elevation in GFAP expression in the SNr (data not shown) so
to explore this possibility we utilised previously generated tissue
from animals bearing a full 6-OHDA-induced lesion in which a
robust inflammatory response is seen. As shown in Supplementary
Figure 1, despite a significant elevation in GFAP immunoreactivity
in the SNr on the lesion side, there was no significant increase in
FGF20 immunoreactivity. Therefore, while resident astrocytes ex-
press FGF20, it seems most likely that those infiltrating the region
in response to the lesion do not, arguing against any compensatory
increase in endogenous FGF20 levels to combat the lesion. Never-
theless, driving enhanced production of FGF20 in the remaining
resident astrocytes remains a worthy pursuit in search of a poten-
tial protective effect in PD.
The protective effects of FGF20 in vitro are known to be medi-
ated through activation of FGFRs (Murase and McKay, 2006;
Ohmachi et al., 2003). To elucidate which FGFRs might mediate the
in vivo neuroprotective effects of FGF20, we examined which ones
co-localised with TH-positive dopaminergic neurons in the SNc.
Consistent with previous reports that FGFR2 was localised purely to
astrocytes in the SNc and SNr (Chadashvili and Peterson, 2006;
Chadi et al., 2008), we found TH-positive neurons were devoid of
FGFR2 expression. The three remaining subtypes (FGFR1, 3 and 4)
were all expressed on dopaminergic neurons in the SNc. The
presence of FGFR1 corroborates previous findings both in rodent
(Sleeman et al., 2012) and human (Walker et al., 1998). Importantly,
FGFR1 expression is retained on residual dopaminergic neurons in
the SNc from PD brain (Walker et al., 1998) supporting FGFR1 as a
potential target for therapeutic intervention. In support of our
findings with FGFR3, mRNA encoding FGFR3 was previously noted
in the SNc (Belluardo et al., 1997; Claus et al., 2004a), although
cellular localisation was not specified. Regarding FGFR4, mRNA
encoding this receptor was noted in adult rodent brain (Cool et al.,
2002), with a preferential localisation suggested in the medial
habenula (Itoh et al., 1994). We likewise observed high levels of
FGFR4 immunoreactivity within the medial habenula (data not
shown) but also had clear localisation on TH-positive neurons in
the SNc. Therefore, activation of FGFR1, 3 or 4 remain possible
routes through which FGF20 mediates its neuroprotective effect on
dopamine neurons in the 6-OHDA lesioned rat, regardless of
whether the source of FGF20 is from astrocytes in the SNr or from
exogenous infusion.
In conclusion, these studies have highlighted a protective role
for FGF20 in the SNc and identify astrocytes as one potential source
Fig. 3. FGF20 co-localises with astrocytes, but not dopamine neurons, in the SN. Immunofluorescent images showing (A) lack of FGF20 (red) signal on TH-positive neurons (green)
in the SNc and (B) co-localisation of FGF20 (red) with GFAP (green) in the neighbouring SNr. Images were acquired at:5 magnification (right hand panel in A; scale
bar¼ 200 mm);20 magnification (left panel in A; scale bar¼ 50 mm);40 magnification (B; scale bar¼ 20 mm). (For interpretation of the references to colour in this figure legend,
the reader is referred to the Web version of this article.)
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Fig. 4. FGFR1, 3 and 4 are expressed on dopaminergic neurons in the SNc. Immunofluorescent images showing co-localisation of (A) FGFR1, (B) FGFR2, (C) FGFR3 and (D) FGFR4 with
TH in coronal sections of the adult rat SNc counterstained with the nuclear marker, Hoechst (blue). Intense staining of FGFR1 (red), FGFR3 (green) and FGFR4 (green) is notable on
TH-positive stained cells, while FGFR2 (red) shows no co-localisation with TH. All images were acquired at 40 magnification. Scale bar¼ 20 mm. (For interpretation of the ref-
erences to colour in this figure legend, the reader is referred to the Web version of this article.)
Eugene.L. Boshoff et al. / Neuropharmacology 137 (2018) 156e163162of endogenous FGF20. Future work will consider alternative means
of delivering FGF20 over a longer duration into the SNc for thera-
peutic exploration and will identify different approaches to boost
the levels of endogenous FGF20 in the brain given the cells pro-
ducing FGF20 are retained in PD (Tong et al., 2015).Funding
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